1
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 21, 2006: WO/2006/135627 (19 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck & Co, Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 22, 2006: WO/2006/065601 (17 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


3
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck &Amp Amp Co, February 21, 2008: KR1020077028878

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4

5
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, March 19, 2008: EP1898903-A2

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


6
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck &Amp Co, wenhong yan liangmou, August 13, 2008: CN200580043064

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


7
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibiteurs de lactivite akt, Inhibitors of akt activity. Merck & Co, Merck Sharp & Dohme, Gowling Lafleur Henderson, February 8, 2011: CA2610888

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


8
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck &Amp Co, zou feng liang mou, February 25, 2009: CN200680020507

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


9

10
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R, Manley Peter J, Bilodeau Mark T: Inhibitors of akt activity. Merck & Co, September 5, 2007: EP1827436-A2

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...



Click the thumbnails below to visualize the patent trend.